FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Calabrese Jeffrey		 2. Date of Event Requiring Statement (MM/DD/YYYY)
10/29/2021 

 3. Issuer Name and Ticker or Trading Symbol

AERIE PHARMACEUTICALS INC [AERI]
(Last)        (First)        (Middle)

C/O AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BLVD., SUITE 400		 4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                          _____ 10% Owner
___X___ Officer (give title below)        _____ Other (specify below)
Vice President of Finance /
(Street)

DURHAM, NC 27703      

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)
 

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		2. Amount of Securities Beneficially Owned
(Instr. 4)		3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 8019 D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)		2. Date Exercisable and Expiration Date
(MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		4. Conversion or Exercise Price of Derivative Security5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)  (1)6/17/2029 Common Stock 14400 $33.29 D  
Stock Option (right to buy)  (2)8/14/2029 Common Stock 7200 $23.97 D  
Stock Option (right to buy)  (3)11/1/2031 Common Stock 6257 $11.02 D  
Explanation of Responses:
(1) These options have vested, or are scheduled to vest, subject to the reporting person's continued employment with the issuer through the applicable vesting date, with respect to 25% of the option on June 17, 2020, and monthly in substantially equal installments over the next 36 months thereafter.
(2) These options have vested, or are scheduled to vest, subject to the reporting person's continued employment with the issuer through the applicable vesting date, in substantially equal installments on each of the first 48 monthly anniversaries of August 14, 2019.
(3) These options have vested, or are scheduled to vest, subject to the reporting person's continued employment with the issuer through the applicable vesting date, in substantially equal installments on each of the first 48 monthly anniversaries of November 1, 2021.
Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Calabrese Jeffrey
C/O AERIE PHARMACEUTICALS, INC.
4301 EMPEROR BLVD., SUITE 400
DURHAM, NC 27703

Vice President of Finance
Signatures
s/ John LaRocca, Attorney-in-Fact for Jeffrey Calabrese11/8/2021
**Signature of Reporting PersonDate
Aerie Pharmaceuticals (NASDAQ:AERI)
Gráfica de Acción Histórica
De May 2024 a Jun 2024 Haga Click aquí para más Gráficas Aerie Pharmaceuticals.
Aerie Pharmaceuticals (NASDAQ:AERI)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024 Haga Click aquí para más Gráficas Aerie Pharmaceuticals.